Publications
Detailed Information
Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Chul-Kee | - |
dc.contributor.author | Lee, Se-Hoon | - |
dc.contributor.author | Han, Jung Ho | - |
dc.contributor.author | Kim, Chae-Yong | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Paek, Sun Ha | - |
dc.contributor.author | Kim, Dong Gyu | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.contributor.author | Kim, Il Han | - |
dc.contributor.author | Jung, Hee-Won | - |
dc.date.accessioned | 2012-06-25T04:45:37Z | - |
dc.date.available | 2012-06-25T04:45:37Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2009-12 | - |
dc.identifier.citation | BMC Cancer, Vol.9, p. 450 | - |
dc.identifier.issn | 1471-2407 | - |
dc.identifier.other | 91855 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77378 | - |
dc.description.abstract | Background: We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA). To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas. Methods: A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in the study. These patients were treated with either radiotherapy alone or radiotherapy followed by PCV chemotherapy after surgery. Five prognostic factors, including histological subsets, age, performance status, extent of resection, and treatment modality were incorporated into the RPA. The final nodes of RPA were grouped according to their survival times, and the Kaplan-Meier graphs are presented as the final set of prognostic groups. Results: Four risk groups were defined based on the clinical prognostic factors excluding age, and split variables were all incorporated into the RPA. Survival analysis showed significant differences in mean survival between the different groups: 163.4 months (95% CI: 144.9-182.0), 109.5 months (86.7-132.4), 66.6 months (50.8-82.4), and 27.7 months (16.3-39.0), respectively, from the lowest to the highest risk group (p = 0.00). Conclusion: The present study shows that RPA grouping with clinical prognostic factors can successfully predict the survival of patients with WHO grade III glioma. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | BioMed Central | - |
dc.title | Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김재용 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 백선하 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.contributor.AlternativeAuthor | 김일한 | - |
dc.contributor.AlternativeAuthor | 김동규 | - |
dc.contributor.AlternativeAuthor | 정희원 | - |
dc.contributor.AlternativeAuthor | 한정호 | - |
dc.contributor.AlternativeAuthor | 박철기 | - |
dc.identifier.doi | 10.1186/1471-2407-9-450 | - |
dc.citation.journaltitle | BMC Cancer | - |
dc.description.citedreference | Chow E, 2009, INT J RADIAT ONCOL, V73, P1169, DOI 10.1016/j.ijrobp.2008.05.067 | - |
dc.description.citedreference | Scheithauer BW, 2008, BRAIN PATHOL, V18, P307, DOI 10.1111/j.1750-3639.2008.00179.x | - |
dc.description.citedreference | *CBTRUS, 2008, STAT REP PRIM BRAIN | - |
dc.description.citedreference | van den Bent MJ, 2007, NEUROL CLIN, V25, P1089, DOI 10.1016/j.ncl.2007.07.013 | - |
dc.description.citedreference | Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4 | - |
dc.description.citedreference | Stupp R, 2007, CRIT REV ONCOL HEMAT, V63, P72, DOI 10.1016/j.critrevonc.2007.03.003 | - |
dc.description.citedreference | Nomiya T, 2007, J NEUROSURG, V106, P575 | - |
dc.description.citedreference | Compostella A, 2007, J NEURO-ONCOL, V81, P295, DOI 10.1007/s11060-006-9232-z | - |
dc.description.citedreference | Miller CR, 2006, J CLIN ONCOL, V24, P5419, DOI 10.1200/JCO.2006.08.1497 | - |
dc.description.citedreference | Cairncross G, 2006, J CLIN ONCOL, V24, P2707, DOI 10.1200/JCO.2005.04.3414 | - |
dc.description.citedreference | Mirimanoff RO, 2006, J CLIN ONCOL, V24, P2563, DOI 10.1200/JCO.2005.04.5963 | - |
dc.description.citedreference | Gulbas H, 2006, JPN J CLIN ONCOL, V36, P193, DOI 10.1093/jjco/hyl007 | - |
dc.description.citedreference | BENT MJ, 2006, J CLIN ONCOL, V24, P2715 | - |
dc.description.citedreference | Lamborn KR, 2004, NEURO-ONCOLOGY, V6, P227, DOI 10.1215/S1152851703000620 | - |
dc.description.citedreference | van den Bent MJ, 2003, J CLIN ONCOL, V21, P2525, DOI 10.1200/JCO.2003.12.015 | - |
dc.description.citedreference | Tortosa A, 2003, CANCER, V97, P1063, DOI 10.1002/cncr.11120 | - |
dc.description.citedreference | Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215 | - |
dc.description.citedreference | KLEIHUES P, 2002, J NEUROPATHOL EXP NE, V61, P226 | - |
dc.description.citedreference | Thomas D, 2001, J CLIN ONCOL, V19, P509 | - |
dc.description.citedreference | Prados MD, 1999, J CLIN ONCOL, V17, P3389 | - |
dc.description.citedreference | Scott CB, 1998, INT J RADIAT ONCOL, V40, P51 | - |
dc.description.citedreference | Gaspar L, 1997, INT J RADIAT ONCOL, V37, P745 | - |
dc.description.citedreference | CELLI P, 1994, NEUROSURGERY, V35, P1018 | - |
dc.description.citedreference | HILDEBRAND J, 1994, NEUROLOGY, V44, P1479 | - |
dc.description.citedreference | CELLI P, 1994, NEUROSURGERY, V35, P1034 | - |
dc.description.citedreference | KLEIHUES P, 1993, BRAIN PATHOL, V3, P255 | - |
dc.description.citedreference | NIJJAR TS, 1993, CANCER, V71, P4002 | - |
dc.description.citedreference | CURRAN WJ, 1993, J NATL CANCER I, V85, P704 | - |
dc.description.citedreference | LEVIN VA, 1990, INT J RADIAT ONCOL, V18, P321 | - |
dc.description.citedreference | OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649 | - |
dc.description.tc | 2 | - |
dc.identifier.wosid | 000273839700001 | - |
dc.identifier.scopusid | 2-s2.0-74549147277 | - |
dc.citation.startpage | 450 | - |
dc.citation.volume | 9 | - |
dc.identifier.sci | 000273839700001 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Park, Chul-Kee | - |
dc.contributor.affiliatedAuthor | Han, Jung Ho | - |
dc.contributor.affiliatedAuthor | Kim, Chae-Yong | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Paek, Sun Ha | - |
dc.contributor.affiliatedAuthor | Kim, Dong Gyu | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.contributor.affiliatedAuthor | Kim, Il Han | - |
dc.contributor.affiliatedAuthor | Jung, Hee-Won | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | ANAPLASTIC ASTROCYTOMA | - |
dc.subject.keywordPlus | NERVOUS-SYSTEM | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | BRAIN METASTASES | - |
dc.subject.keywordPlus | VINCRISTINE PCV | - |
dc.subject.keywordPlus | TUMORS | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.